Rhythm Pharmaceuticals, Inc. RYTM Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$55.64M-17.1% | -$47.51M+10.2% | -$52.9M-13.4% | -$46.63M+5.8% | -$49.5M-14.3% | ||
| $23.1M+19.9% | $19.27M+2.4% | $18.81M+18.5% | $15.88M+23.5% | $12.86M+21.8% | ||
| $8.11M— | —— | $6.6M-15.7% | $7.83M+1,240% | -$687K— | ||
| $3.09M-37.4% | $4.93M+101% | $2.45M— | $0-100% | $575K-88.1% | ||
| -$5.62M-548% | $1.26M-88.6% | $11.02M-16.9% | $13.26M+465% | -$3.63M-124% | ||
| -$435K-164% | $681K-87.0% | $5.24M+197% | -$5.42M-5,218% | -$102K+97.9% | ||
| -$178K— | —— | —— | —— | $0— | ||
| -$145K— | —— | —— | —— | -$1.29M— | ||
| -$44.19M-74.0% | -$25.39M+4.6% | -$26.62M-14.2% | -$23.31M+42.2% | -$40.35M-114% | ||
| $42.2M+107% | $20.35M-92.4% | $267.85M+894% | $26.95M-19.6% | $33.52M-49.5% | ||
| $99.25M+92.2% | $51.65M-16.0% | $61.5M-24.1% | $80.99M+38.8% | $58.33M-33.4% | ||
| $57.05M— | —— | -$246.35M-556% | $54.04M+118% | $24.81M— | ||
| $4.29M-20.6% | $5.4M-3.1% | $5.57M+28.6% | $4.33M-6.1% | $4.62M+21.2% | ||
| $0-100% | $22.88M— | —— | —— | $34.03M+30.1% | ||
| $8.46M— | —— | —— | —— | $0— | ||
| -$5.4M— | —— | $189.3M— | —— | $32.5M-15.2% | ||
| $448K+600% | $64K-78.9% | $304K+209% | -$279K-13,850% | -$2K-100% | ||
| $7.92M— | $0+100% | -$83.36M-382% | $29.55M+74.3% | $16.96M-59.3% | ||
| $113K+3.7% | $109K+4.8% | $104K-1.0% | $105K-4.5% | $110K-0.9% | ||
| $252K-7.4% | $272K-10.5% | $304K-19.8% | $379K-1.0% | $383K0.0% | ||
| -$1.35M— | —— | —— | $1.71M— | $0— | ||
| -$145K— | —— | —— | —— | -$1.29M— | ||
| $330K+354% | -$130K+63.9% | -$360K+28.0% | -$500K-725% | $80K+167% | ||
| $487K-82.0% | $2.71M— | —— | $6.8M+112% | $3.2M-43.8% | ||
| -$1.44M+22.6% | -$1.86M-9.4% | -$1.7M-43.8% | -$1.18M+34.0% | -$1.79M+16.4% | ||
| $4.58M-0.8% | $4.62M-2.7% | $4.74M-18.5% | $5.82M+7.6% | $5.41M-0.7% | ||
| -$178K— | —— | —— | —— | $0— | ||
| $42.2M+107% | $20.35M-92.4% | $267.85M+894% | $26.95M-19.6% | $33.52M-49.5% | ||
| $99.25M+92.2% | $51.65M-16.0% | $61.5M-24.1% | $80.99M+38.8% | $58.33M-33.4% | ||
| —— | $47.16M0.0% | $47.16M0.0% | $47.16M0.0% | $47.16M— | ||
| $1.25M+125,000% | $1K-99.9% | $729K— | $0-100% | $854K— | ||
| $448K+600% | $64K-78.9% | $304K+209% | -$279K-13,850% | -$2K-100% | ||
| —— | $0— | $0— | $0— | $0-100% | ||
| $1.1M-17.1% | $1.33M-3.1% | $1.38M+1.9% | $1.35M+2.0% | $1.32M-1.3% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Rhythm Pharmaceuticals, Inc. generate?
- Rhythm Pharmaceuticals, Inc. (RYTM) generated -$119.5M in operating cash flow over the trailing twelve months.
- Where does Rhythm Pharmaceuticals, Inc.'s cash flow data come from?
- Every line is extracted from Rhythm Pharmaceuticals, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
